it remains unlicensed by the MHRA and EMA as of mid-2025 and is only available within approved clinical trials
For Canadians researching peptide options, Retatrutide offers several advantages beyond raw efficacy
Curr Med Res Opin 24(1):275286 Kong F, Wu T, Dai J, Zhai Z, Cai J, Zhu Z et al (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimers disease models: a systematic review and meta-analysis of preclinical studies
The glucagon receptor activation appears to contribute to quicker metabolic response, while the GIP component may help reduce early nausea that can slow initial adaptation to GLP-1 medications
If side effects persist despite dose adjustments, physicians often recommend stopping the medication
24 This hormone is mainly synthesized in L-cells of the intestinal lining